JP2020507623A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507623A5
JP2020507623A5 JP2019563680A JP2019563680A JP2020507623A5 JP 2020507623 A5 JP2020507623 A5 JP 2020507623A5 JP 2019563680 A JP2019563680 A JP 2019563680A JP 2019563680 A JP2019563680 A JP 2019563680A JP 2020507623 A5 JP2020507623 A5 JP 2020507623A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
peptide
human
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507623A (ja
JP7438757B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052822 external-priority patent/WO2018141969A1/en
Publication of JP2020507623A publication Critical patent/JP2020507623A/ja
Publication of JP2020507623A5 publication Critical patent/JP2020507623A5/ja
Priority to JP2024019238A priority Critical patent/JP2024056838A/ja
Application granted granted Critical
Publication of JP7438757B2 publication Critical patent/JP7438757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563680A 2017-02-06 2018-02-05 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター Active JP7438757B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024019238A JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17154889 2017-02-06
EP17154889.4 2017-02-06
PCT/EP2018/052822 WO2018141969A1 (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019238A Division JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Publications (3)

Publication Number Publication Date
JP2020507623A JP2020507623A (ja) 2020-03-12
JP2020507623A5 true JP2020507623A5 (https=) 2021-03-04
JP7438757B2 JP7438757B2 (ja) 2024-02-27

Family

ID=57995050

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563680A Active JP7438757B2 (ja) 2017-02-06 2018-02-05 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター
JP2024019238A Pending JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024019238A Pending JP2024056838A (ja) 2017-02-06 2024-02-13 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Country Status (8)

Country Link
US (4) US20200087374A1 (https=)
EP (3) EP3577462B1 (https=)
JP (2) JP7438757B2 (https=)
AU (2) AU2018216033B2 (https=)
CA (2) CA3051293A1 (https=)
ES (1) ES2927977T3 (https=)
SG (2) SG11201906943VA (https=)
WO (2) WO2018141970A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6982395B2 (ja) * 2017-03-16 2021-12-17 三洋化成工業株式会社 インターロイキン１０の産生量増加剤
WO2019104391A1 (en) * 2017-12-01 2019-06-06 St Vincent's Institute Of Medical Research Type 1 diabetes treatment
CA3149581A1 (en) * 2019-08-30 2021-03-04 Gert Wensvoort Q-er peptide
JP6895148B1 (ja) * 2020-03-31 2021-06-30 クラシエホールディングス株式会社 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット
CN117106029A (zh) * 2020-06-08 2023-11-24 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
CN112345770A (zh) * 2020-11-06 2021-02-09 苏州大学附属第一医院 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用
KR102718109B1 (ko) * 2021-10-01 2024-10-17 (주)케어젠 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도
JP2024537244A (ja) * 2021-10-05 2024-10-10 バイオテンプト ベー．フェー 好ましくは血糖コントロールと組み合わせた、血管新生コントロール
AU2023308137A1 (en) 2022-07-12 2025-01-30 Biotempt B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
EP1578352A2 (en) * 2002-03-27 2005-09-28 University of Utah Research Foundation Elastin prevents occlusion of body vessels by vascular smooth muscle cells
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
GB0412174D0 (en) 2004-06-01 2004-06-30 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
JP2015507193A (ja) * 2012-02-01 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性結合物の結合パートナーを検出するための方法
EP2626704B1 (en) * 2012-02-08 2015-11-18 Mehmet Ali Soylemez Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin
EP2836841B1 (en) * 2012-04-12 2022-01-05 B.R.A.H.M.S GmbH Prognosis of adverse events in patients with suspected chronic heart failure
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2897327A1 (en) * 2013-01-08 2014-07-17 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
WO2014145836A1 (en) * 2013-03-15 2014-09-18 Health Diagnostic Laboratory, Inc. Method of generating an index score for mbl deficiency to predict cardiodiabetes risk
CN104371003B (zh) 2013-08-15 2025-09-02 上海市第一人民医院 预防和治疗炎症的小分子多肽及其应用
WO2015140317A1 (en) * 2014-03-21 2015-09-24 Sanofi New markers for the assessment of the risk for development of a cardiovascular disorder

Similar Documents

Publication Publication Date Title
JP2020507623A5 (https=)
JP2011526886A5 (https=)
JP2007001987A5 (https=)
JP2017532343A5 (https=)
CA2596597A1 (en) Method for stimulation collagen synthesis and/or kgf expression
JP2006506942A5 (https=)
JP2006514104A5 (https=)
JP2012506442A5 (https=)
JP2006149365A5 (https=)
NO20071369L (no) Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv
JP2005516072A5 (https=)
JP2019533722A5 (https=)
HRP20140586T1 (hr) Peptidi za lijeäśenje beta-amiloidoze
JP2016536357A5 (https=)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2018538356A5 (https=)
HRP20191965T1 (hr) Stabilizirani polipeptidi faktora rasta slični inzulinu
JP2020513810A5 (https=)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2010536714A5 (https=)
JP2009516654A5 (https=)
MX2008009493A (es) Peptido novedoso y uso del mismo.
JP2007535910A5 (https=)
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
JP2010512326A5 (https=)